However, in a phase III clinical trial conducted in TB pericarditis patients, two‐thirds of whom had TB‐HIV coinfection, the MIP vaccine did not show significant therapeutic effects but demonstrated significant adverse events. The gene discussed is MIP; the disease is tuberculosis.